Payment overview · 2025
General Payments
$1,098.29
66 reported records · 18 companies
Healthcare provider profile · identity verified
Eric K Fowler, MD
Allopathic & Osteopathic Physicians|Family Medicine · REEDSVILLE, PA · NPI 1740217611
Verified facts
What the public records show
CMS Open Payments records show Eric K Fowler, MD received $1,098.29 in general payments during 2025 across 66 reported records.
PFIZER INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $270.15 | 24.6% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.34 | 14.4% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.45 | 13.1% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $124.90 | 11.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.50 | 8.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $59.16 | 5.4% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.01 | 3.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.45 | 3.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.36 | 2.9% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$21.62 | 2.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.80 | 1.8% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19.21 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.91 | 1.6% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $17.42 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.26 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.22 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.82 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.71 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,098.29 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $190.32 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $158.34 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $158.34 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $124.90 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $116.13 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $96.34 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $79.83 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $79.83 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $79.83 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.88 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.50 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $65.75 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $59.16 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.93 | 5 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $51.66 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $34.33 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 340 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
340 | 66 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
340 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 914 | 220 |
| Atorvastatin Calcium | Atorvastatin Calcium | 761 | 217 |
| Omeprazole | Omeprazole | 735 | 199 |
| Losartan Potassium | Losartan Potassium | 601 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 591 | 143 |
| Metoprolol Succinate | Metoprolol Succinate | 507 | 133 |
| Metoprolol Tartrate | Metoprolol Tartrate | 399 | 99 |
| Lisinopril | Lisinopril | 388 | 104 |
| Potassium Chloride | Potassium Chloride | 386 | 103 |
| Eliquis | Apixaban | 340 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 323 | 91 |
| Metformin Hcl | Metformin Hcl | 296 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 290 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 82 |
| Glimepiride | Glimepiride | 286 | 76 |
| Metformin Hcl Er | Metformin Hcl | 267 | 76 |
| Prednisone | Prednisone | 263 | 162 |
| Escitalopram Oxalate | Escitalopram Oxalate | 237 | 64 |
| Furosemide | Furosemide | 236 | 70 |
| Gabapentin | Gabapentin | 225 | 63 |
| Sertraline Hcl | Sertraline Hcl | 218 | 56 |
| Simvastatin | Simvastatin | 208 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 47 |
| Lovastatin | Lovastatin | 201 | 49 |
| Lorazepam | Lorazepam | 188 | 49 |
| Meloxicam | Meloxicam | 181 | 49 |
| Montelukast Sodium | Montelukast Sodium | 177 | 50 |
| Trazodone Hcl | Trazodone Hcl | 171 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 156 | 93 |
| Azithromycin | Azithromycin | 151 | 127 |
| Finasteride | Finasteride | 149 | 40 |
| Allopurinol | Allopurinol | 148 | 46 |
| Famotidine | Famotidine | 140 | 43 |
| Carvedilol | Carvedilol | 139 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 47 |
| Tramadol Hcl | Tramadol Hcl | 124 | 33 |
| Bupropion Xl | Bupropion Hcl | 113 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 36 |
| Jardiance | Empagliflozin | 108 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 26 |
| Celecoxib | Celecoxib | 103 | 31 |
| Atenolol | Atenolol | 98 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 20 |
| Ozempic | Semaglutide | 92 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 17 |
| Ezetimibe | Ezetimibe | 81 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 22 |
| Alendronate Sodium | Alendronate Sodium | 73 | 16 |
| Xarelto | Rivaroxaban | 71 | 11 |
| Spironolactone | Spironolactone | 69 | 18 |
| Nystatin | Nystatin | 68 | 36 |
| Mupirocin | Mupirocin | 67 | 41 |
| Myrbetriq | Mirabegron | 66 | 13 |
| Alprazolam | Alprazolam | 62 | 12 |
| Fenofibrate | Fenofibrate | 61 | 12 |
| Mirtazapine | Mirtazapine | 59 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 41 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 19 |
| Amoxicillin | Amoxicillin | 55 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 13 |
| Buspirone Hcl | Buspirone Hcl | 49 | 15 |
| Nitroglycerin | Nitroglycerin | 49 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | 17 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 14 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 41 | 12 |
| Cefuroxime | Cefuroxime Axetil | 40 | 39 |
| Warfarin Sodium | Warfarin Sodium | 39 | 13 |
| Hydrocortisone | Hydrocortisone | 38 | 19 |
| Propranolol Hcl | Propranolol Hcl | 37 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Fluconazole | Fluconazole | 33 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 13 |
| Valsartan | Valsartan | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Rybelsus | Semaglutide | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 13 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Jantoven | Warfarin Sodium | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Linzess | Linaclotide | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 13 | 13 |
| Topiramate | Topiramate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,098.29 · 66 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, Andembry, BEXSERO, CAMZYOS, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Korlym, LEQEMBI, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VALTOCO, VOQUEZNA, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error